You are currently not logged in   |   [login]
News & Events
Request information
For information about additional Gyros seminars and presentations in your area contact your local representative

In Focus

Select:
Event:

 4th Annual Gyrolab Seminar

 Johannesberg's Castle, Uppsala, Sweden, 10-12 March 2010 [more]
News:

Gyros and SCRUM sign distribution agreement for the

Japanese market

Gyros® AB, the leading provider of automated micro-immunoassays for the development of biotherapeutics, is pleased to announce the signing of an exclusive distribution agreement with SCRUM, a major supplier to the Japanese life-science market. Under the terms of the agreement, SCRUM will market, sell and fully support the Gyros product range, within the Japanese biopharmaceutical, contract research and contract manufacturing industries.

[more]
Info:

4th Annual Gyrolab Seminar

View our updated list of confirmed speakers! The 4th Annual Gyrolab Seminar will be held in Johannesbergs Castle, Uppsala, Sweden, March 10-12, 2010

[more]
News:

Gyros and DI Biotech sign distribution agreement for the Korean market

Gyros® AB, the leading provider of automated micro-immunoassays for therapeutic protein development, is pleased to announce the signing of a distribution agreement with DI Biotech, the leading supplier to the Korean life-science market. Under the terms of the agreement, DI Biotech will market and provide full support for Gyros' proprietary technology, Gyrolab®, to the Korean pharmaceutical, biotech, CRO and CMO industries.

[more]
Info:

Addressing ligand binding assay deficiencies

Gyrolab system designed to circumvent the problems associated with conventional methods

As published in GEN, 1 August 2009, by Kevin Brady, Senior Principal Scientist, Pfizer, UK

The quantification of proteins is an integral part of biopharmaceutical R&D. From the crude quantitation of hybridoma expression profiles of monoclonal antibodies, to quantitative determination of biologic drugs and protein biomarkers in clinical trials, ligand binding assays have become a research standard...

[more]
News:

Gyros raises SEK 80 million to accelerate the commercialization of its Gyrolab systems for the cost-efficient development of biopharmaceuticals

Gyros AB, the leading provider of automated micro-immunoassays for therapeutic protein development, announces that it has raised SEK 80 million (approximately €7.5m) in an equity fundraising led by SLS Invest, the Company's leading shareholder. The new funds will enable Gyros to drive the further commercialization of its Gyrolab technology.

[more]
News:

View on demand webinar: Accelerate your therapeutic protein development in a GxP environment

Recording of a 45-minute webinar on assay and system validation hosted by Marian Kelley, contributing author of DeSilva white paper*, on behalf of Gyros® AB on June 16th, 2009.

[more]
News:

Video highlights of ‘The 3rd Gyrolab Seminars 2009’

 [more]
|< < 1 2 3 4 5  > >|
page of 6  [Go!]